Evidence map›Paper›PMID 37100705›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2023

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.

D R VanDevanter, E T Zemanick, M W Konstan, C L Ren, K Odem-Davis, I Emerman, J Young, N Mayer-Hamblett, CHEC-SC Study Group

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03350828 (The CHEC-SC Cohort Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03350828 active not recruitingnot on this map

The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

TypeobservationalSponsorNicole HamblettRan2018 to 2026Enrolled5,000ConditionsCystic Fibrosis
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

D R VanDevanterCase Western Reserve University School of Medicine, Cleveland, OH United States. Electronic address: dutch.vandevanter@gmail.com.
E T ZemanickUniversity of Colorado, Anschutz Medical Campus, Aurora CO United States.
M W KonstanCase Western Reserve University School of Medicine, Cleveland, OH United States; Rainbow Babies and Children's Hospital, Cleveland, OH United States.
C L RenChildren's Hospital of Philadelphia, Philadelphia, PA United States.
K Odem-DavisSeattle Children's Hospital, Seattle, WA United States.
I EmermanSeattle Children's Hospital, Seattle, WA United States.
J YoungSeattle Children's Hospital, Seattle, WA United States.
N Mayer-HamblettSeattle Children's Hospital, Seattle, WA United States; University of Washington, Seattle, WA United States.
CHEC-SC Study Group
Seattle Children's Hospital · USChildren's Hospital of Philadelphia · USRainbow Babies & Children's Hospital · USUniversity of Colorado Anschutz Medical Campus · USUniversity School · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Project 3 - Personalized cystic fibrosis treatment strategies with synergistic therapies Identified in vitro.P01HL128192 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN · 2016 to 2020
$12.2M
NCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002548NHLBI NIH HHS P01 HL128192NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

objectiveTo assess the feasibility of enrolling people with CF (pwCF) taking the CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) in clinical trials of a new modulator.

methodsPwCF receiving ETI at CHEC-SC study (NCT03350828) enrollment were surveyed for interest in 2-week to 6-month placebo- (PC) and active-comparator (AC) modulator studies. Those taking inhaled antimicrobials (inhABX) were surveyed for interest in PC inhABX studies.

resultsOf 1791 respondents, 75% [95% CI 73, 77] would enroll in a 2-week PC modulator study versus 51% [49, 54] for a 6-month study; 82% [81, 84] and 63% [61, 65] would enroll in 2-week and 6 month AC studies; 77% [74, 80] of 551 taking inhABX would enroll in a 2-week PC inhABX study versus 59% [55, 63] for a 6-month study. Previous clinical trial experience increased willingness.

conclusionsStudy designs will affect feasibility of future clinical trials of new modulators and inhABX in people receiving ETI.

Indexed as

Anti-Infective AgentsCystic FibrosisAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorHumansIndolesMutationPyrazolesPyridinesPyrrolidinesQuinolonesAminophenolsAnti-Infective AgentsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftor

Identifiers

PMID37100705
PMCPMC10523954
OpenAlexW4366831933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.